News
Press Releases
.jpg)
-
- 30
- 2022/03
Bring Warm Tide of Solidarity against the Epidemic, Chia Tai Health Donates Supplies to Reinforce the Front Line of Epidemic Prevention and Control
On March 28, Jiangsu Chia tai Health Technology Co., Ltd, a wholly-owned subsidiary of Jiangsu Chia tai Qingjiang Pharmaceutical, donated epidemic prevention materials and food to Hangzhou Road Community, Jingnan Community, Shizhong Health Service Center and Bochi Mountain Community Health Service Center respectively, expressing sincere greetings to front-line epidemic workers and showing the social responsibility and mission of the enterprise.View > -
- 08
- 2022/03
Sino Biopharm Pneumoconiosis Class I Innovative Drug Approved for Clinical
Sino Biopharm (HK.1177) announced on March 8 that TDI01 suspension, a Class I innovative drug developed independently by its subsidiary Beijing Tide Pharmaceutical Co., Ltd, was approved by National Medical Products Administration on March 3, 2022 to conduct clinical trials for pneumoconiosis. According to the official website of the National Medical Products Administration Drug Review Center, TDI01 is an oral small molecule drug with a new target and a new mechanism,View > -
- 08
- 2022/03
CTTQ of Sino Biopharm Donates Epidemic Prevention Supplies in Need to Lianyungang Haizhou District
On the afternoon of March 8, CTTQ Pharmaceutical Group donated 100,000 copies of nucleic acid testing reagents, 12,000 N95 masks and 20,000 pairs of medical rubber gloves to Lianyungang Haizhou District through the donation center of Lianyungang Civil Affairs Bureau to help prevent and control the epidemic in Haizhou District.View > -
- 24
- 2022/02
Sino Biopharm Directors Donate 1.2 Million Medical Surgical Masks to Win the Battle Against Epidemic
President Xi Jinping's important instruction on the fight against the epidemic in Hong Kong has greatly boosted the confidence of Hong Kong people in overcoming the epidemic. Several directors of Sino Biopharm Limited (01177. HK) also responded positively. After donating 70,000 sets of COVID-19 antigen test kits a week ago, on the 23rd, Cheng Cheung Ling and Tse Ping, Vice Chairmen of the Board of Directors of the Company,View > -
- 24
- 2022/02
CTTQ of Sino Biopharm Was Awarded "Excellent" in National Enterprise Technology Center Evaluation
Recently, the National Development and Reform Commission released the "Evaluation Results of National Enterprise Technology Center 2021", and the National Enterprise Technology Center of CTTQ Pharmaceutical Group was awarded "Excellent" among the 1,744 National Enterprise Technology Centers participating in the evaluation nationwide,View > -
- 15
- 2022/02
Sino Biopharm Donates 70,000 Sets of COVID-19 Testing Kits to Support HKSAR's Fight Against Epidemics
Sino Biopharm (01177.HK) announced on the 15th that it has purchased 70,000 sets of COVID-19 antigen testing kits and donated them to the HKSAR Government and the "Hong Kong Community Anti-epidemic Link" respectively, hoping to help Hong Kong fight against the epidemic and alleviate the urgent need of currently overloading testing capacity.View > -
- 14
- 2022/02
Sino Biopharm - Chia Tai Qingjiang Pharmaceuticals Was Listed as One of the "Top 50 Enterprises" in Huai'an City
Recently, Huai'an City held a conference on tackling heavy and mega projects and optimizing business environment, which released the list of "Top 50 enterprises in Huai'an City in 2021", and Chia Tai Qingjiang ranked 16th in the list with excellent results, up 4 places compared with last year.View > -
- 18
- 2022/01
CTTQ and XtalPi Enter into Collaboration Focusing on the Development of Difficult Small Molecule Antitumor Drugs
Recently, CTTQ, a subsidiary of Sino Biopharm, and XtalPi, a drug discovery and development company driven by intelligent and automated technologies, announced a strategic collaboration to jointly develop new small molecule drugs for the treatment of malignant tumors against difficult targets.View > -
- 12
- 2022/01
JPM Healthcare Annual Meeting: Sino Biopharm Expected to Achieve Double-Digit Revenue Growth This Year
As one of the first Chinese pharmaceutical companies to participate in the annual JP Morgan Healthcare Conference, Sino Biopharm made another appearance at the conference at 9 a.m. EST on the 11th (10 p.m. BST on the 11th). In a video presentation, Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm, revealed that the company is expected to achieve double-digit revenue growth this year, driven by its core products such as PD1, Anlotinib and liver disease.View > -
- 11
- 2022/01
Nanjing CTTQ's LOGO "NJCTTQ" Won the Madrid Trademark International Registration
Recently, Nanjing CTTQ's "NJCTTQ" LOGO was successfully registered in Madrid. This is another breakthrough in the"going out" of intellectual property rights after the international layout of patent PCT.View >